Multicentre evaluation of a new point-of-care test for the determination of NT-proBNP in whole blood
-
Christian Zugck
Abstract
Background: The Roche CARDIAC proBNP point-of-care (POC) test is the first test intended for the quantitative determination of N-terminal pro-brain natriuretic peptide (NT-proBNP) in whole blood as an aid in the diagnosis of suspected congestive heart failure, in the monitoring of patients with compensated left-ventricular dysfunction and in the risk stratification of patients with acute coronary syndromes.
Methods: A multicentre evaluation was carried out to assess the analytical performance of the POC NT-proBNP test at seven different sites.
Results: The majority of all coefficients of variation (CVs) obtained for within-series imprecision using native blood samples was below 10% for both 52 samples measured ten times and for 674 samples measured in duplicate. Using quality control material, the majority of CV values for day-to-day imprecision were below 14% for the low control level and below 13% for the high control level. In method comparisons for four lots of the POC NT-proBNP test with the laboratory reference method (Elecsys proBNP), the slope ranged from 0.93 to 1.10 and the intercept ranged from 1.8 to 6.9. The bias found between venous and arterial blood with the POC NT-proBNP method was ≤5%. All four lots of the POC NT-proBNP test investigated showed excellent agreement, with mean differences of between −5% and +4%. No significant interference was observed with lipaemic blood (triglyceride concentrations up to 6.3mmol/L), icteric blood (bilirubin concentrations up to 582μmol/L), haemolytic blood (haemoglobin concentrations up to 62mg/L), biotin (up to 10mg/L), rheumatoid factor (up to 42IU/mL), or with 50 out of 52 standard or cardiological drugs in therapeutic concentrations. With bisoprolol and BNP, somewhat higher bias in the low NT-proBNP concentration range (<175ng/L) was found. Haematocrit values between 28% and 58% had no influence on the test result. Interference may be caused by human anti-mouse antibodies (HAMA) types 1 and 2. No significant influence on the results with POC NT-proBNP was found using volumes of 140–165μL. High NT-proBNP concentrations above the measuring range of the POC NT-proBNP test did not lead to false low results due to a potential high-dose hook effect.
Conclusions: The POC NT-proBNP test showed good analytical performance and excellent agreement with the laboratory method. The POC NT-proBNP assay is therefore suitable in the POC setting.
Clin Chem Lab Med 2006;44:1269–77.
References
1. Sharpe N, Doughty R. Epidemiology of heart failure and ventricular dysfunction. Lancet 1998; 352(Suppl 1):3–7.10.1016/S0140-6736(98)90012-5Search in Google Scholar
2. Lloyd-Jones DM, Larson MG, Leip EP, Beiser A, D'Agostino RB, Kannel WB, et al. Lifetime risk for developing congestive heart failure – The Framingham Heart Study. Circulation 2002; 106:3068–72.10.1161/01.CIR.0000039105.49749.6FSearch in Google Scholar
3. Nieminen MS, Böhm M, Cowie MR, Drexler H, Filippatos GS, Jondeau G, et al. Executive summary of the guidelines for the diagnosis and treatment of acute heart failure. The Task Force on Acute Heart Failure of the European Society of Cardiology. Eur Heart J 2005; 26:384–416.10.1093/eurheartj/ehi044Search in Google Scholar
4. Swedberg K, Cleland J, Dargie H, Drexler H, Follath F, Komajda M, et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005). The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J 2005; 26:1115–40.10.1093/eurheartj/ehi204Search in Google Scholar
5. Lainchbury JG, Campbell E, Frampton CM, Yandle TG, Nicholls MG, Richards AM. Brain natriuretic peptide and N-terminal brain natriuretic peptide in the diagnosis of heart failure in patients with acute shortness of breath. J Am Coll Cardiol 2003; 42:728–35.10.1016/S0735-1097(03)00787-3Search in Google Scholar
6. Bayés-Genís A, Santaló-Bel M, Zapico-Muñiz E, López L, Cotes C, Bellido J, et al. N-Terminal probrain natriuretic peptide (NT-proBNP) in the emergency diagnosis and in-hospital monitoring of patients with dyspnoea and ventricular dysfunction. Eur J Heart Fail 2004; 6:301–8.10.1016/j.ejheart.2003.12.013Search in Google Scholar PubMed
7. Januzzi JL, Camargo CA, Anwaruddin S, Baggish AL, Chen AA, Krauser DG, et al. The N-terminal pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am J Cardiol 2005; 95:948–54.10.1016/j.amjcard.2004.12.032Search in Google Scholar PubMed
8. Januzzi JL, van Kimmenade R, Lainchbury J, Bayes-Genis A, Ordóñez-Llanos J, Santaló-Bel M, et al. NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients. Eur Heart J 2006; 27:330–7.10.1093/eurheartj/ehi631Search in Google Scholar PubMed
9. Hobbs FD, Davis RC, Roalfe AK, Hare R, Davies MK, Kenkre JE. Reliability of N-terminal pro-brain natriuretic peptide assay in diagnosis of heart failure: cohort study in representative and high risk community populations. Br Med J 2002; 324:1498–502.10.1136/bmj.324.7352.1498Search in Google Scholar PubMed PubMed Central
10. Wright SP, Doughty RN, Pearl A, Gamble GD, Whalley GA, Walsh HJ, et al. Plasma amino-terminal pro-brain natriuretic peptide and accuracy of heart-failure diagnosis in primary care. A randomized, controlled trial. J Am Coll Cardiol 2003; 42:1793–800.10.1016/j.jacc.2003.05.011Search in Google Scholar PubMed
11. Bettencourt P. NT-proBNP and BNP: biomarkers for heart failure management. Eur J Heart Fail 2004; 6:359–63.10.1016/j.ejheart.2004.01.008Search in Google Scholar
12. Hartmann F, Packer M, Coats AJS, Fowler MB, Krum H, Mohacsi P, et al. Prognostic impact of plasma N-terminal pro–brain natriuretic peptide in severe chronic congestive heart failure. A substudy of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Trial. Circulation 2004; 110:1780–6.10.1161/01.CIR.0000143059.68996.A7Search in Google Scholar
13. Kirk V, Bay M, Parner J, Krogsgaard K, Herzog TM, Boesgaard S, et al. N-Terminal proBNP and mortality in hospitalized patients with heart failure and preserved vs. reduced systolic function: data from the prospective Copenhagen Hospital Heart Failure Study (CHHF). Eur J Heart Fail 2004; 6:335–41.10.1016/j.ejheart.2004.01.002Search in Google Scholar
14. Gardner RS, Chong KS, Morton JJ, McDonagh TA. N-Terminal brain natriuretic peptide, but not anemia, is a powerful predictor of mortality in advanced heart failure. J Card Fail 2005; 11(Suppl):47–53.10.1016/j.cardfail.2005.04.008Search in Google Scholar
15. George J, Patal S, Wexler D, Abashidze A, Shmilovich H, Barak T, et al. Circulating erythropoietin levels and prognosis in patients with congestive heart failure: comparison with neurohormonal and inflammatory markers. Arch Intern Med 2005; 165:1304–9.10.1001/archinte.165.11.1304Search in Google Scholar
16. Kellett J. The prediction of in-hospital mortality by amino terminal pro-brain natriuretic peptide (NT-proBNP) levels and other independent variables in acutely ill patients with suspected heart disease. Eur J Int Med 2005; 16:195–9.10.1016/j.ejim.2004.10.017Search in Google Scholar
17. Troughton RW, Frampton CM, Yandle TG, Espiner EA, Nicholls MG, Richards AM. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 2000; 355:1126–30.10.1016/S0140-6736(00)02060-2Search in Google Scholar
18. Groenning BA, Nilsson JC, Sondergaard L, Pedersen F, Trawinski J, Baumann M, et al. Detection of left ventricular enlargement and impaired systolic function with plasma N-terminal pro brain natriuretic peptide concentrations. Am Heart J 2002; 143:923–9.10.1067/mhj.2002.122168Search in Google Scholar
19. Hunt PJ, Espiner EA, Nicholls MG, Richards AM, Yandle TG. The role of the circulation in processing pro-brain natriuretic peptide (proBNP) to amino-terminal BNP and BNP-32. Peptides 1997; 18:1475–81.10.1016/S0196-9781(97)00245-3Search in Google Scholar
20. Yeo KT, Wu AH, Apple FS, Kroll MH, Christenson RH, Lewandrowski KB, et al. Multicenter evaluation of the Roche NT-proBNP assay and comparison to the Biosite Triage BNP assay. Clin Chim Acta 2003; 338:107–15.10.1016/j.cccn.2003.08.016Search in Google Scholar PubMed
21. van der Merwe D, Henly R, Lane G, Field R, Frenneaux M, Dunstan F, et al. Effect of different sample types and stability after blood collection of N-terminal pro-B-type natriuretic peptide as measured with Roche Elecsys System. Clin Chem 2004; 50:779–80.10.1373/clinchem.2003.025064Search in Google Scholar
22. The National Academy of Clinical Biochemistry. Laboratory medicine practice guidelines: biomarkers of acute coronary syndrome and heart failure. Draft Guidelines, Version 2. http://www.nacb.org.Search in Google Scholar
23. Blick KE. Economics of point-of-care (POC) testing for cardiac markers and B-natriuretic peptide (BNP). Point Care J 2005; 4:11–4.10.1097/01.poc.0000157182.34907.89Search in Google Scholar
24. Mueller C, Scholer A, Laule-Kilian K, Martina B, Schindler C, Buser P, et al. Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. N Engl J Med 2004; 350:647–54.10.1056/NEJMoa031681Search in Google Scholar
25. Müller-Bardorff M, Sylvén C, Rasmanis G, Jørgensen B, Collinson PO, Waldenhofer U, et al. Evaluation of a point-of-care system for quantitative determination of troponin T and myoglobin. Clin Chem Lab Med 2000; 38:567–74.10.1515/CCLM.2000.083Search in Google Scholar
26. Collinson PO, Jørgensen B, Sylvén C, Haass M, Chwallek F, Katus HA, et al. Recalibration of the point-of-care test for Cardiac T Quantitative with Elecsys Troponin T 3rd generation. Clin Chim Acta 2001; 307:197–203.10.1016/S0009-8981(01)00428-4Search in Google Scholar
27. Dempfle CE, Schraml M, Besenthal I, Hansen R, Gehrke J, Korte W, et al. Multicenter evaluation of a new point-of-care test for the quantitative determination of D-dimer. Clin Chim Acta 2001; 307:211–8.10.1016/S0009-8981(01)00436-3Search in Google Scholar
28. Collinson PO, Barnes SC, Gaze DC, Galasko G, Lahiri A, Senior R. Analytical performance of the N terminal pro B type natriuretic peptide (NT-proBNP) assay on the Elecsys 1010 and 2010 analysers. Eur J Heart Fail 2004; 6:365–8.10.1016/j.ejheart.2004.01.011Search in Google Scholar PubMed
29. Sokoll LJ, Baum H, Collinson PO, Gurr E, Haass M, Luthe H, et al. Multicenter analytical performance evaluation of the Elecsys proBNP assay. Clin Chem Lab Med 2004; 42:965–72.10.1515/CCLM.2004.157Search in Google Scholar PubMed
30. Fairbanks VF, Ziesmer SC, O'Brian PC. Methods for measuring plasma hemoglobin in micromolar concentration compared. Clin Chem 1992; 38:132–40.10.1093/clinchem/38.1.132Search in Google Scholar
©2006 by Walter de Gruyter Berlin New York
Articles in the same Issue
- Multiplexed testing in the autoimmunity laboratory
- Uncertainty calculation for calibrators and controls of laboratory diagnostic assays
- Westgard multirule for calculated laboratory tests
- Frequency of a single nucleotide (A2317G) and 56-bp variable number of tandem repeat polymorphisms within the deoxyribonuclease I gene in five ethnic populations
- The influence of genetic polymorphisms of cytochrome P450 3A5 and ABCB1 on starting dose- and weight-standardized tacrolimus trough concentrations after kidney transplantation in relation to renal function
- Apolipoprotein B gene 3′VNTR polymorphism: association with plasma lipids and coronary heart disease in Han Chinese
- Paraoxonase-1 (PON1) activity, but not PON1Q192R phenotype, is a predictor of coronary artery disease in a middle-aged Serbian population
- A modified method of prothrombin time/International Normalised Ratio determination in capillary blood and monitoring oral anticoagulant therapy
- Inhibition of the ubiquitin-proteasome system: a new avenue for atherosclerosis
- Lipid peroxidation and antioxidative status in β-thalassemia major patients with or without hepatitis C virus infection
- Role of serum S100B as a predictive marker of fatal outcome following isolated severe head injury or multitrauma in males
- Preanalytical and analytical variation of surface-enhanced laser desorption-ionization time-of-flight mass spectrometry of human serum
- Effect of nitrogen mustard, a vesicant agent, on lymphocyte energy metabolism
- Partitioning reference values of several Gaussian subpopulations with unequal prevalence – a procedure with computer program support
- Biovariability of plasma adiponectin
- Multicentre evaluation of a new point-of-care test for the determination of NT-proBNP in whole blood
- Innotrac Aio!: a point-of-care or a routine analyzer? Analytical performance and plasma/whole blood comparison
- Serologic associations of anti-cytoplasmic antibodies identified during anti-nuclear antibody testing
- The importance of metrological traceability on the validity of creatinine measurement as an index of renal function: International Federation of Clinical Chemistry and Laboratory Medicine (IFCC)
- Effect of seropositive rheumatoid factor on cardiac troponin I measurement using the Access® Immunoassay Analyzer
Articles in the same Issue
- Multiplexed testing in the autoimmunity laboratory
- Uncertainty calculation for calibrators and controls of laboratory diagnostic assays
- Westgard multirule for calculated laboratory tests
- Frequency of a single nucleotide (A2317G) and 56-bp variable number of tandem repeat polymorphisms within the deoxyribonuclease I gene in five ethnic populations
- The influence of genetic polymorphisms of cytochrome P450 3A5 and ABCB1 on starting dose- and weight-standardized tacrolimus trough concentrations after kidney transplantation in relation to renal function
- Apolipoprotein B gene 3′VNTR polymorphism: association with plasma lipids and coronary heart disease in Han Chinese
- Paraoxonase-1 (PON1) activity, but not PON1Q192R phenotype, is a predictor of coronary artery disease in a middle-aged Serbian population
- A modified method of prothrombin time/International Normalised Ratio determination in capillary blood and monitoring oral anticoagulant therapy
- Inhibition of the ubiquitin-proteasome system: a new avenue for atherosclerosis
- Lipid peroxidation and antioxidative status in β-thalassemia major patients with or without hepatitis C virus infection
- Role of serum S100B as a predictive marker of fatal outcome following isolated severe head injury or multitrauma in males
- Preanalytical and analytical variation of surface-enhanced laser desorption-ionization time-of-flight mass spectrometry of human serum
- Effect of nitrogen mustard, a vesicant agent, on lymphocyte energy metabolism
- Partitioning reference values of several Gaussian subpopulations with unequal prevalence – a procedure with computer program support
- Biovariability of plasma adiponectin
- Multicentre evaluation of a new point-of-care test for the determination of NT-proBNP in whole blood
- Innotrac Aio!: a point-of-care or a routine analyzer? Analytical performance and plasma/whole blood comparison
- Serologic associations of anti-cytoplasmic antibodies identified during anti-nuclear antibody testing
- The importance of metrological traceability on the validity of creatinine measurement as an index of renal function: International Federation of Clinical Chemistry and Laboratory Medicine (IFCC)
- Effect of seropositive rheumatoid factor on cardiac troponin I measurement using the Access® Immunoassay Analyzer
